Pharmacological strategies for relapse prevention in schizophrenia

Psychiatry

Volumn 6, Issue 9, 2007, Pages 351-356

  Barnes, Thomas R E ^a,b   Drake, Richard ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

antipsychotic medication; medication adherence; relapse prevention; schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE;

COMORBIDITY; DOCTOR PATIENT RELATION; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; TARDIVE DYSKINESIA;

EID: 34548531032     PISSN: 14761793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mppsy.2007.07.002     Document Type: Review

References (31)

1. Marder S.R., and Wirshing D.A. Maintenance treatment. In: Hirsch S.R., and Weinberger D.R. (Eds). Schizophrenia. 2nd edn. (2003), Blackwell, Oxford
2. Davis J.M., Janicak P.G., Singla A., et al. Maintenance antipsychotic medication. In: Barnes T.R.E. (Ed). Antipsychotic drugs and their side effects (1993), Academic Press, London
3. Leucht S., and Kane J.M. Measurement-based psychiatry: definitions of response, remission, stability and relapse in schizophrenia. J Clin Psychiatry 67 (2006) 1813-1814
4. Csernansky J.G., and Schuchart E.K. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16 (2002) 473-484
5. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114 (2006) 3-13
6. Viguera A.C., Baldessarini R.J., Hegarty J.D., van Kammen D.P., and Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 54 (1997) 49-55
7. Boshes R.A., and Manschrek T.C. Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophr Bull 28 (2002) 203-222
8. Gilbert P.L., Harris M.J., McAdams L.A., and Jeste D.V. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 52 (1995) 173-188
9. National Institute for Clinical Excellence. Schizophrenia: full national clinical guideline on core interventions in primary and secondary care (2003), National Collaborating Centre for Mental Health, Gaskell & British Psychological Society, London
10. Bosveld-van Haandel L.J., Sloof C.J., and van den Bosch R.J. Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments. Acta Psychiatr Scand 103 (2001) 335-346
11. Robinson D., Woerner M.G., Alvir J.M., et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56 (1999) 241-247
12. Lehman A.F., Steinwachs D.M., and Co-Investigators of the PORT Project. Translating research into practice: the schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 24 (1998) 1-10
13. Barbui C., Saraceno B., Liberati A., et al. Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials. Eur Psychiatry 11 (1996) 306-313
14. Gitlin M., Neuchterlein K., Subotnik K., et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 158 (2001) 1835-1842
15. Gaebel W., Janner M., Fromann N., et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 53 (2002) 145-159
16. Wunderink L., Nienhuis F.J., Wiersma D., et al. Treatment delay, short-term response and outcome of two medication treatment strategies in a first onset schizophrenia study: the MESIFOS RCT. Schizophr Bull 31 (2005) 507
17. Prudo R., and Blum H.M. Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Centre of the International Pilot Study of Schizophrenia. Br J Psychiatry 150 (1987) 345-354
18. Wiersma D., Nienhuis F.J., Slooff C.J., and Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull 24 (1998) 75-85
19. Curson D.A., Barnes T.R.E., Bamber R.W.K., et al. Long-term depot maintenance of chronic schizophrenic outpatients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. Br J Psychiatry 146 (1985) 464-480
20. Kavanagh D.J., McGrath J., Saunders J.B., Dore G., and Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 62 (2002) 743-755
21. Bebbington P.E. The content and context of compliance. Int Clin Psychopharmacol 9 suppl 5 (1995) 41-50
22. Cramer J.A., and Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49 (1998) 196-201
23. Nosé M., Barbui C., Gray R., and Tansella M. Meta-analysis of clinical interventions for reducing treatment non-adherence in psychoses. Br J Psychiatry 183 (2003) 197-206
24. O'Donnell C., Donohoe G., Sharkey L., et al. Compliance therapy: a randomised controlled trial in schizophrenia. Br Med J 327 (2003) 834-837
25. McIntosh A.M., Conlon L., Lawrie S.M., and Stanfield A.C. Compliance therapy for schizophrenia. Cochrane Database Syst Rev Issue 3. (2006) 10.1002/14651858.CD003442.pub2 Art. No.: CD003442
26. Leucht S., Barnes T.R.E., Kissling W., et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and explorative meta-analysis of randomized, controlled trials. Am J Psychiatry 160 (2003) 1209-1222
27. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
28. Jones P.B., Barnes T.R.E., Davies L., et al. A randomized controlled trial of effect on quality of life of second generation versus first generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 63 (2006) 1079-1087
29. Tihonen J., Wahlbeck K., Lonnqvist J., et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Br Med J 333 (2006) 224-229
30. National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal No. 43. (2002), NICE, London
31. Schooler N., Rabinowitz J., Davidson M., et al. Early psychosis global working group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 162 (2005) 947-953